

Development of anti-fibrosis therapeutics for systemic sclerosis using SOS1- RAS interaction-specific blockade

Kyungpook National University



IMMUNOLOGY	Hit
Product Type	Chemical synthesis product
Indication	1st indication: Systemic Sclerosis, anti-Fibrosis
Target	A strategy to selectively inhibit the SOS1/RAS signaling pathway
MoA(Mechanism of Action)	SOS1 targeting inhibition → Anti-fibrosis → Targeted therapy for systemic sclerosis
Competitiveness	<ul style="list-style-type: none"> • RAS protein is a key factor in the treatment of RAS in the anticancer drug market, but there are many high-frequency Ras mutations in carcinomas with high mortality. • To overcome this, products using the upper signal SOS1 are the pan-KRAS small molecule inhibitors (BI-3406 and BI-1701963) from Boehringer Ingelheim and small molecule inhibitors that target the allosteric RAS binding site (BAY-293, Bayer AG). From a different point of view, our team tried to find new indications for regulating SOS1 and targeting fibrosis regardless of mutation.
Development Stage	Hit
Route of Administration	Enteral administration